Background: It is unclear if differential chemotherapy effects exist on overall survival (OS), response rate (RR) and toxicity depending on primary tumour origin [oesophageal versus oesophago-gastric junction (OGJ) versus gastric adenocarcinoma].
suggested that there is a relationship between primary tumour origin (PTO) and long-term outcome with cancers detected earlier in the oesophagus compared with those arising from around the cardia and stomach. However, the relevance of this is unclear in advanced disease setting, as very few data exist in the literature on this issue. Therefore, the need to exclude adenocarcinoma of oesophageal origin from future phase III studies in advanced disease setting remains controversial. In this pooled analysis, our aims are to evaluate whether the effects of chemotherapy were different in patients with advanced adenocarcinoma of oesophageal, OGJ and gastric origins in relation to overall survival (OS), objective response rate (ORR) and toxicity. patients with locally advanced or metastatic cancer of oesophagus, OGJ or stomach. The first study randomised 274 patients from 1992 to 1995 to ECF [epirubicin, cisplatin and protracted venous infusion (PVI) 5-fluorouracil (5-FU)] or FAMTX (fluorouracil, doxorubicin and methotrexate) [13, 14] . The second study randomised 580 patients from 1995 to 1998 to ECF or MCF [mitomycin C (MMC), cisplatin and 5-FU] [15] . The third study randomised 254 patients from 1994 to 2001 to PVI 5-FU or PVI 5-FU plus MMC [16] . The fourth study randomised 1002 patients in a 2 · 2 factorial design to ECF, ECX (epirubicin, cisplatin and capecitabine), EOF (epirubicin, oxaliplatin and 5-FU) and EOX (epirubicin, oxaliplatin and capecitabine) [17] . A maximum treatment period of 24 weeks was planned in all four study protocols.
All four RCTs had broadly similar eligibility criteria. Patients were required to have histologically confirmed inoperable adenocarcinoma, squamous cell carcinoma (SCC) or undifferentiated carcinoma of the oesophagus, OGJ or stomach; adequate haematological, renal and hepatic function and Eastern Cooperative Oncology Group performance status (PS) zero to two. The main eligibility differences were that the first study excluded patients with SCC [14] , whereas the third study recruited patients with inoperable cancer due to co-morbid conditions [16] . Before randomisation, written informed consent was obtained from all patients. All four studies were approved by the Scientific and Research Ethics Committees of the participating institutions.
For the purpose of this analysis, only eligible patients with adenocarcinoma histology who received one or more dose of chemotherapy were included.
end points and statistical considerations OS was calculated from the date of randomisation until death from any cause or censored at last follow-up using the Kaplan-Meier method [18] . Comparisons of survival curves among three PTOs were carried out using log-rank test [19] . Survival analyses were carried out in the eligible population only. Multivariate survival analysis was carried out using Cox proportional hazard model [20] and stratified for treatment centres. The following factors were included: PTO (oesophagus versus OGJ versus stomach), treatment arms, PS (0, 1 versus 2), serum alkaline phosphatase (<100 versus ‡100 U/l) and liver metastases (presence versus absence) based on previously identified prognostic factors in advanced OG cancer [21] .
Objective response was assessed according to the World Health Organisation (WHO) criteria in three trials [14] [15] [16] and Response Evaluation Criteria in Solid Tumors (RECIST) criteria in the fourth trial [17] . WHO (bidimensional) and RECIST (unidimensional) criteria are regarded as largely comparable [22] . ORRs were compared among the three PTOs using Fisher's exact test. For toxicity, a chemotherapy-specific toxicity composite end point (TCE) was constructed as a surrogate for undesirable toxic effects to the cytotoxic drugs used in the studies (fluoropyrimidines, platinum compounds, anthracyclines and MMC). TCE was defined as the first occurrence of grade 3 or 4 diarrhoea, neutropenia, febrile neutropenia, fever, infection, nausea and vomiting or grade ‡2 renal or neurotoxicity. The number of patients developing TCE with different PTOs was compared using Fisher's exact test. Multivariate logistic regression was carried out to identify predictive factors for chemotherapy response or developing TCE. Apart from the factors used in the multivariate survival analysis, age and gender were also included. Time to TCE was calculated from the time of randomisation to development of first event qualifying for TCE and was compared among PTOs using log-rank test.
As multiple statistical testing was carried out, a two-sided P value of <0.01 was considered significant for all end points and 99% confidence intervals (CI) were quoted. Analyses were carried out using SPSS package version 15 (SPSS Inc., Chicago, IL).
results
Of the 2110 patients randomised, 1775 (84%) patients had adenocarcinoma with oesophageal (n = 485), OGJ (n = 457) and gastric (n = 833) origins and were eligible for this pooled analysis. Figure 1 shows the trial profile in this analysis. Table 1 shows the baseline demographics. Significantly more patients with gastric adenocarcinoma had macroscopic peritoneal metastasis than those with oesophageal cancer (P < 0.0001), whereas significantly more patients with oesophageal adenocarcinoma had pulmonary metastasis (P < 0.0001) than those with gastric origin.
At the time of data cut-off, 1576 (89%) patients had died. The median follow-up for the surviving patients was 30.7 months. The original article Annals of Oncology median survival for the whole group (n = 1775) was 9.1 months. One-year survival was 36.8% (95% CI 34.2% to 39%) and 2-year survival was 13.2% (95% CI 12.3% to 15%). Figure 2 shows the OS for the whole group. There were no significant OS differences among the three PTO groups (P = 0.677). Figure 3 shows the OS according to PTO. The median survival was 9.5, 9.3 and 8.7 months in oesophageal, OGJ and gastric cancers, respectively. One-year survival rates were 36.8%, 37.9% and 36.1%, respectively, and 2-year survival rates were 12.4%, 14.3% and 13.1%, respectively. Table 2 shows the multivariate analysis. PS 2, presence of liver metastasis and elevated serum alkaline phosphatase remained as significant prognostic factors for OS. PTO was not a significant prognostic factor. Table 3 shows the ORR and TCE according to PTO. The ORR was 44.1%, 41.1% and 35.6% in oesophageal, OGJ and gastric cancers, respectively. On univariate analysis, oesophageal adenocarcinoma had a significantly higher ORR (P = 0.003) compared with gastric cancer, but not OGJ (P = 0.07). However, this was not significant after controlling for other covariates [P = 0.11 (oesophageal) and P = 0.27 (OGJ) compared with gastric cancer; Table 2 ]. Table 4 shows the frequency of toxicity according to PTO. There were no differences in the proportion of patients' experiencing TCE according to PTO either on univariate (Table 3) or multivariate ( Table 2) analyses. No significant predictive factors were identified for the development of TCE. Time to developing TCE was also not different among the three groups (P = 0.906). Figure 4 shows time to developing TCE according to PTO.
discussion
Our pooled analysis represents probably the largest dataset for patients with advanced OG cancer recruited in phase III RCTs.
In our analysis, we did not find any significant difference on multivariate analyses in OS, ORR and toxic effects among patients with advanced adenocarcinoma of oesophageal, OGJ and gastric origins. With our large sample size (n = 1775), one could detect an OS difference of 8% between oesophagus or OGJ versus gastric origin (at least 80% power; two-sided a = 0.05) or 10% survival difference (at least 80% power; twosided a = 0.01). Therefore, it would be unlikely to find a clinically meaningful differential chemotherapy effect, even if larger clinical trials are carried out. However, as our data were derived from a predominantly Caucasian population, one cannot extrapolate our data to the Asian population.
The strength of this analysis lies in the data which were derived from four of the largest RCTs ever conducted in the advanced disease setting [14] [15] [16] [17] . Eighty-nine per cent of patients are dead and therefore the survival data are mature. All patients received fluoropyrimidine-based chemotherapy with the majority given platinum compounds. The studies included have established ECF initially and EOX subsequently as one of the reference treatment regimens in advanced OG cancer [14, 15, 17] , thus these studies are landmark studies in this disease area. In addition, the older age group with co-morbid conditions was included in the study evaluating PVI 5-FU with or without MMC [16] . Therefore, the cohort of patients included in this pooled analysis reflects the wide spectrum of contemporary patients seen in routine clinical practice. In Annals of Oncology original article addition, by using pooled analysis, as compared with single trial, it improved statistical power and limits random error. Although the four trials in our pooled analysis had broadly similar eligibility criteria, there were invariably some differences in the patient demographics among trials. We accounted for this heterogeneity by including, in a mandatory manner, the individual treatment arms into the multivariate models, thus essentially stratifying for individual treatment arms and therefore individual trials. In addition, ECF was evaluated in three of the four trials [14, 15, 17] and patients receiving ECF had consistently similar survival in all these trials (P = 0.851), suggesting that the survival results were relatively homogeneous among trials in our pooled analysis.
We restricted our analysis to adenocarcinoma histology alone, as SCC may have completely different biological behaviour. Even within adenocarcinoma of OG origin, there are epidemiological and aetiopathogenetic differences between oesophageal adenocarcinoma and OGJ/gastric adenocarcinoma [23] . There has been a striking five-fold rise in incidence for oesophageal adenocarcinoma in white males [24] , but the increasing incidence was much less pronounced for carcinoma of the gastric cardia [23] . Although the same time trend was also seen in the black males, the incidence is much less than white males [23, 24] . However, a very low incidence rate of oesophageal adenocarcinoma is found in Asian people, even in those who live in the United States, in contrast to their much higher incidence of gastric cardia adenocarcinoma [23] . Oesophageal adenocarcinoma is strongly associated with gastro-oesophageal reflux disease and body mass index and inversely associated with Helicobacter pylori and antioxidant intake. In contrast, these factors had no convincing association with gastric adenocarcinoma [23] . Gene expression profiling had also shown in a study by Gomes et al. [25] some differences among adenocarcinomas of oesophageal, OGJ and gastric origins. It appeared that OGJ adenocarcinoma clustered together with gastric adenocarcinoma, mainly of intestinal type. Conversely, oesophageal adenocarcinoma gene expression profiles dispersed among the malignant diseases, indicating the absence of a common expression profile. In this study by Gomes et al. [25] , however, the majority of patients had localised OG cancer. It is possible that once tumours have reached an advanced stage with metastases occurring, the origin of the tumour might no longer have a significant impact on outcome, as further somatic mutations and activation of cancer survival pathways might render these tumours 'equally unresponsive' to cytotoxic drugs, producing similarly poor survival for patients with advanced OG cancer.
There have been some suggestions that patients with oesophageal cancer responded differently to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors compared with gastric cancers. There appeared to be more responses seen in oesophageal and OGJ cancers to gefitinib or erlotinib monotherapy [26] [27] [28] [29] [30] [31] [32] . However, most of these uncontrolled phase II studies had small number of patients and the 95% CI for ORRs greatly overlapped among studies. Therefore, there is no conclusive evidence at the moment of a differential effect to EGFR blockade according to PTO in upper GI cancers. The relatively low response rates of 1%-17% seen with gefitinib or erlotinib, albeit in second or subsequent line setting, suggested For survival, risk ratios >1 means worse survival compared with control groups. For response rates, risk ratios <1 means worse response rates compared with control groups. For toxicity composite end points, risk ratios >1 means more frequent toxicity compared with control groups. original article Annals of Oncology that other therapeutic targets should be focussed on. Interestingly, in the on-going ToGA study (Trastuzumab gastric adenocarcinoma study) evaluating cisplatin/ fluoropyrimidines 6 trastuzumab, human epidermal growth factor receptor 2 (HER2) positivity was significantly higher in OGJ compared with gastric adenocarcinoma. Whether there is a differential benefit of trastuzumab between OGJ and gastric cancer remains to be seen. Yet again, oesophageal cancer was excluded from this study [33] . In our analysis, the survival curves of patients with oesophageal, OGJ and gastric cancers almost completely overlapped with each other and the median survival, 1-and 2-year survival rates were very similar among the three PTO groups. In our previous analysis, we identified PS, serum alkaline phosphatase, presence of liver and peritoneal metastases as the four most significant prognostic factors in advanced OG cancer [21] . Not only did we account for the survival differences between locally advanced versus metastatic disease, we sought to determine which metastatic sites had the greatest prognostic influence [21] . We had therefore applied the same prognostic model into our current analysis. However, the pattern of spread differed between oesophageal and gastric cancer patients with more peritoneal spread in gastric and more pulmonary metastases in oesophageal cancer patients. In view of the imbalance of the presence of peritoneal metastases at baseline, we elected not to include this factor in the multivariate analysis. Interestingly, if peritoneal metastasis was controlled for in the multivariate model, oesophageal adenocarcinoma would have a significantly Response rates were calculated using total number of patients with each primary tumour origin as the denominator (intention-to-treat). However, there were patients who died before their first response assessment or did not have measurable disease; therefore, the total percentage did not add up to 100%. OGJ, oesophago-gastric junction; CI, confidence interval. 
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worse survival than gastric cancer (hazard ratio 1.22; 99% CI 1.03-1.44; P = 0.003). Nevertheless, by controlling peritoneal metastasis, one would be removing a significant number of gastric cancer patients with poor prognosis in the analysis. As a result, one would be comparing oesophageal adenocarcinoma patients with only the good prognosis gastric cancer patients (those with peritoneal metastasis removed). The consequent worse survival found with oesophageal adenocarcinoma would not be an accurate representation of tumour origin as an independent prognostic factor. Although there was a slight trend towards more stomatitis with OGJ adenocarcinoma, the difference was mainly limited to grades 1 and 2. Anaemia was also more frequent in gastric cancer-more likely to be relating to bleeding from primary tumour, rather than increased chemotherapy-related anaemia in gastric cancer. No other significant differences were observed in either haematological or nonhaematological toxic effects among the three PTO groups. In particular, nausea and vomiting was not different among the three PTOs, as oesophageal cancer patients might conceivably had more vomiting, in view of the obstructive nature of the primary tumour. TCE, acting as a surrogate for the particularly undesirable serious side-effects, was not different among the three PTO groups.
The main limitation in our pooled analysis would be the definition of the PTO groups. Our trial database was reliant on reporting from investigators participating in the trials and we did not verify the primary tumour site against source data, i.e. original endoscopy reports. Nevertheless, in a multicentre randomised trial setting, there was unlikely to be systematic reporting bias which might significantly influence our results. Furthermore, our data derived from treatment with cytotoxic drugs, therefore these data cannot be extrapolated to studies with biological agents, as discussed previously with HER2 and EGFR blockade.
In conclusion, despite epidemiological, aetiopathogenetic and gene expression profile differences, our large multicentre RCT dataset did not demonstrate any significant differences in survival, objective tumour response and toxic effects on multivariate analyses among patients with advanced oesophageal, OGJ and gastric adenocarcinoma. Additional molecular factors are likely to be at play affecting the response of these tumours to cytotoxic chemotherapy at the advanced metastatic stage. Until distinct molecular pathways have been identified and targeted therapeutics appropriately developed, it may not be justified to distinguish patients according to PTO in advanced OG adenocarcinoma, either in clinical trials or routine clinical practice. Patients with oesophageal adenocarcinoma should be considered for enrolment into phase III studies of advanced gastric and OGJ cancers. 
